Growing return potential in biopharmaceutical royalties, says Sagard exec

'Even in an inflationary environment, we're able to benefit from a returns perspective as a result of those prices increasing higher than we may have anticipated,' Sagard's Raja Manchanda says.

DealsFund ManagersInvestorsSpeciality FinanceAcquisitionFund ManagersInvestors